Regulation & Compliance

In a stunning rebuke, a judge warns of 'criminal consequences' as a charity's fight for survival puts government secrecy and accountability on trial.

A new AI trading bot, MoneyFlare, claims to make crypto investing effortless. But can a 'zero learning curve' platform truly tame a notoriously volatile market?

With new CTO Zack Moy, AI-native TPA Elysian aims to solve insurance's most complex data problems, blending machine intelligence with human expertise.

As Catholic Church bankruptcy settlements advance, survivors face a complex reality: long-awaited payouts aided by high-cost litigation funding firms.

First Tech hires former Federal Reserve counsel Steven Wright as CLO, a strategic move to navigate post-merger growth and complex financial regulations.

The new DSP leverages 100% first-party HCP data, script-lift measurement, and sustainability metrics to offer unparalleled precision and performance.

Agena Bioscience's new test helps labs align with updated ACMG recommendations for cystic fibrosis, aiming for more equitable and efficient carrier screening.

Christine Cooper's appointment to the SIIA board places a fierce cost-containment advocate at the heart of policy-making for self-insured health plans.

Heineken’s new smartband at Coachella uses music data to spark friendships, blending tech and sociability while raising questions about data privacy.

A new partnership promises to help banks deploy AI for fraud and compliance in weeks, tackling legacy systems and rising regulatory pressure.

Coro's new AI integration lets users manage security via ChatGPT, but this leap in convenience comes with a new frontier of potential security risks.

The Christopher Street Project’s massive rally on the National Mall united thousands to demand action and directly engage lawmakers on trans rights.

Kekst CNC appoints 20-year veteran Lyndsey Estin as Co-CEO, signaling a strategic focus on AI and cybersecurity in a major leadership shift.

As millions grapple with Cannabis Use Disorder, a small biotech's lead drug enters Phase 3 trials, promising the first-ever FDA-approved treatment.

PMGC Holdings touts major acquisitions and a promising biotech pipeline, but a look at its financials reveals a high-stakes bet on future growth.

Analyses reveal the EPA allows pesticides with high cancer risks on the market without warning labels, raising major public health and legal questions.

With a fortified balance sheet and promising clinical data, Monopar Therapeutics is advancing its lead drug, ALXN1840, toward a pivotal NDA filing.

The Diocese of Albany agrees to a $148 million settlement for 440 abuse claims, a major step in its bankruptcy and a victory for survivor advocates.

Amidst record staff shortages, FranklinCovey claims its trust-based leadership model can heal the healthcare system, one hospital team at a time.

New data reveals a slight drop in Tennessee's youth suicide rates, yet the crisis persists as a leading cause of death, sparking urgent calls for action.